| Vol. 8.30 – 12 August, 2020 |
| |
|
|
| Scientists report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among 45 healthy adults, 18 to 55 years of age, randomized to receive two doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine that encoded trimerized SARS-CoV-2 spike glycoprotein receptor-binding domain. [Nature] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| In a dual-center, two-cohort study, researchers combined single-cell RNA-sequencing and single-cell proteomics of whole blood and peripheral blood mononuclear cells to determine changes in immune cell composition and activation in mild vs. severe COVID-19 over time. [Cell] |
|
|
|
| Investigators experimentally measured how all amino-acid mutations to the receptor binding protein affect expression of folded protein and its affinity for ACE2. [Cell] |
|
|
|
| Scientists performed single-cell RNA sequencing in peripheral blood samples of five healthy donors and 13 patients with COVID-19, including moderate, severe and convalescent cases. [Nature Immunology] |
|
|
|
| The authors investigated how complement interacted with the platelet/neutrophil extracellular traps (NETS)/thrombin axis, using COVID-19 specimens, cell-based inhibition studies and NETs/human aortic endothelial cell co-cultures. [Journal of Clinical Investigation] |
|
|
|
| By employing single-cell analysis of the immune cell composition of two severe-stage COVID-19 patients prior to and following tocilizumab-induced remission, investigators identified a monocyte subpopulation that contributes to the inflammatory cytokine storms. [Nature Communications] |
|
|
|
| Scientists describe potent inhibitory effects on content release and infection by chimeric vesicular stomatitis virus containing the envelope proteins of Zaire ebolavirus or SARS-CoV-2 elicited by Apilimod and Vacuolin-1, small-molecule inhibitors of the main endosomal phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, PIKfyve. [Proceedings of the National Academy of Sciences of the United States of America] |
| | Researchers report on a systems-level blood immunomonitoring study of 37 adult patients diagnosed with COVID-19 and followed with up to 14 blood samples from acute to recovery phases of the disease. [Cell Reports Medicine] |
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| The ability of immune mobilizing monoclonal T cell receptors Against Virus-envelope to activate and redirect polyclonal T cells towards cells containing integrated HBV and cells infected with hepatitis B virus was assessed using cytokine secretion assays and imaging‐based killing assays. [Hepatology] |
|
|
|
| Scientists showed that lipopolysaccharide in combination with IFNγ, inhibited PINK1-dependent mitophagy in macrophages through a STAT1-dependent activation of the inflammatory caspases 1 and 11. [Journal of Clinical Investigation] |
|
|
|
| The authors report that mouse survival of peritoneal Escherichia coli sepsis was compromised by long-chain polyphosphates, and improved with bacterial polyphosphatekinase deficiency or neutralization using recombinant exopolyphosphatase. [Nature Communications] |
|
|
|
| Researchers show rapid antiretroviral therapy in acute and early HIV was acceptable and effective, with 69.0% of participants starting ART within seven days of HIV diagnosis disclosure and 88.1% achieving suppression by 48 weeks. [Clinical Infectious Diseases] |
|
|
|
| Typhi strain were stained with a 33-metal-labeled antibody panel for mass cytometry analyses of the early chromatin modifications modulated by S. Typhi. [Scientific Reports] |
| |
|
|
|
| The authors summarize current knowledge of the links between HIV-1 infection and immunometabolism, and they discuss the potential opportunities and challenges for therapeutic interventions. [Nature Reviews Immunology] |
|
|
|
|
| Russia’s president Vladimir Putin announced that the country’s health regulator had become the world’s first to approve a coronavirus vaccine for widespread use – but scientists worldwide have condemned the decision as dangerously rushed. [Nature News] |
|
|
|
| RedHill Biopharma Ltd. announced approval from the Mexican Federal Committee for the Protection against Sanitary Risks for the company’s Clinical Trial Authorization application for the Phase II/III study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection and pneumonia. [RedHill Biopharma Ltd.] |
|
|
|
| BioAegis Therapeutics, Inc. announced that it enrolled its first patient in its Phase II study of hospitalized patients with severe COVID-19 pneumonia. [BioAegis Therapeutics, Inc. (GlobeNewswire, Inc.)] |
|
|
|
| IMV, Inc. announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase I clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2. [IMV, Inc.] |
|
|
|
| Novavax, Inc. and Takeda Pharmaceutical Company Limited announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. [Novavax, Inc.] |
|
|
|
| Bayer announced that the FDA has approved Lampit® for use in pediatric patients for the treatment of Chagas disease caused by Trypanosoma cruzi. [Bayer (BusinessWire, Inc.)] |
|
|
|
|
|
|
|
| Princeton University – Princeton, New Jersey, United States |
|
|
|
| Rush University Medical Center – Chicago, Illinois, United States |
|
|
|
| University of Dundee – Dundee, United Kingdom |
|
|
|
| University of Würzburg – Würzburg, Germany |
|
|
|
| Ohio State University – Columbus, Ohio, United States |
|
|
|
|